Hikal Regulatory Approval

Other Announcement

Hikal Other Announcement

Hikal Ltd filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports routine ownership data with no new transaction.

Board Meeting Date

Hikal Board Meeting Date

Hikal's board meets November 3, 2026 to consider September quarter and half-year results. The results are yet to be approved.

Other Announcement

Hikal Other Announcement

Hikal Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as required under SEBI Regulation 31(1)(b).

Management Change

Hikal Management Change

Hikal Limited announced the cessation of Mr. Jai Hiremath as Executive Chairman and the resignation of Mrs. Sugandha Hiremath. Mr. Anish Swadi was appointed as CEO-Animal Health.

Other Announcement

Hikal Other Announcement

Hikal Ltd. has been assigned an ESG rating of "Crisil ESG 65" by Crisil ESG Ratings & Analytics Limited, based on their independent assessment of public data.

Annual General Meeting

Hikal Annual General Meeting

Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.

Regulatory ApprovalSun Pharmaceutical Industries Ltd SUNPHARMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sun Pharmaceutical Industries Regulatory Approval

Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.

Regulatory ApprovalRNFI Services Ltd RNFIAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027